Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Peter Stein Takes Short Path To Director Of US FDA Drug Office

Executive Summary

An industry veteran, Stein has been with agency for only two years; Bob Temple becomes powerful OND "consultant."

Related Content

Historic Output Of Disease-Specific Guidances Is Among Gottlieb's Legacies At US FDA
Scenes From A Shutdown: US FDA Hides It Well
US FDA's Biosimilars Chief Leah Christl Plans Departure
CDER Recruitment Wins Begin Outnumbering Losses
US FDA Office Of New Drugs Likely To Be Headed By Deputy Director Stein
Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions
New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations
Gottlieb: The Next Janet Woodcock Is Waiting To Be Discovered At FDA
'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs
Merck R&D Exec Jumps To US FDA As Office Of New Drugs Deputy Director


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts